Other languages Nanoform Finland Oyj

Equities

NANOFH

FI4000330972

Market Closed - Nasdaq Helsinki Other stock markets 09:18:15 2024-05-03 EDT			5-day change	1st Jan Change
2.07 ^EUR	+1.47%		-3.94%	+30.60%

04-11	Nanoform Finland to Deliver Nanomedicine Technology to Japan	MT
04-11	Nanoform Enters Exclusive Partnership with CBC to Bring Best-In-Class Nanomedicine Technology to Japan	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Nanoform Finland to Deliver Nanomedicine Technology to Japan	04-11
Nanoform Enters Exclusive Partnership with CBC to Bring Best-In-Class Nanomedicine Technology to Japan	04-11
Nanoform Teams Up with PlusVitech to Repurpose Anti-Nausea Drug for Lung Cancer Treatment	04-09
Nanoform Finland plc and Plusvitech Partner to Repurpose Aprepitant as A Treatment for Lung Cancer	04-09
Nanoform Finland Oyj Reports Earnings Results for the Full Year Ended December 31, 2023	02-29
Nanoform Finland Oyj Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-29
Nanoform Finland plc Receives Positive Results from its Own Pre- Clinical, In-Vivo Study of a Nanocrystalline-Enabled Apalutamide Oral Formulation	02-29
Nanoform Announces Important Milestone with Promising Clinical Results for Patient-Centric Nanotechnology-Enhanced Enzalutamide	01-26
Nanoform Finland Starts Clinical Trial for Nanocrystalline Alternative of Prostrate Cancer Drug	01-05
Nanoform Finland plc Commences Relative Bioavailability Study of Nanotechnology-Enhanced Enzalutamide	01-05
Nanoform Finland Oyj Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-22
Nanoform Finland Signs Licensing Deal for AI Technology with AstraZeneca	23-10-23
Nanoform Grant Global STARMAP[®] AI License to AstraZeneca	23-10-23
Nanoform Finland Oyj Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-24
Nanoform and Celanese Demonstrate Enhanced Drug Delivery Through the Power of Smaller Implants	23-06-15
Nanoform Finland Oyj Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-25
Finnish Medicines Agency Renews Nanoform's GMP License and Nanoform Starts Clinical API Manufacturing of Blockbuster Medicine Candidate	23-05-09
Nanoform Finland plc Announces Board Appointments	23-04-12
Nanoform Finland Oyj Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-27
Nanoform Appoints Antonio Da Silva as Chief of Business Operations and Member of the Management Team	22-12-20

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Nanoform Finland Oyj

Equities

NANOFH

FI4000330972

Other languages

Filters